MarketCap
Facebook
X
Telegram
Aptose Biosciences Operativer Cashflow | APTO
Operativer Cashflow Jährlich Aptose Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22 M | -36 M | -44.6 M | -32.3 M | -43.3 M | -33.9 M | -21.6 M | -23.2 M | -10.2 M | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -10.2 M | -44.6 M | -29.7 M |
Operativer Cashflow Vierteljährlich Aptose Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.84 M | - | - | -2.8 M | - | - | -5.78 M | -11.8 M | - | -10.5 M | -13.5 M | -11.3 M | - | -6.98 M | -7.05 M | -9.64 M | - | -8.06 M | -8.82 M | -10.4 M | - | -8.27 M | -7.16 M | -8.11 M | - | -5.18 M | -5.27 M | -4.87 M | - | -4.47 M | -9.18 M | -4.05 M | - | -2.07 M | -2.63 M | -2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -2.07 M | -13.5 M | -7.05 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
BioXcel Therapeutics
BTAI
|
-57.6 M | $ 0.07 | 9.81 % | $ 855 K |  USA |
 |
InflaRx N.V.
IFRX
|
-35.3 M | $ 1.21 | -7.63 % | $ 81.4 M |  Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-1.62 M | $ 1.78 | 16.33 % | $ 1.2 B |  Israel |
 |
22nd Century Group
XXII
|
-7.72 M | $ 1.46 | -10.43 % | $ 269 K | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
127 M | $ 4.82 | 2.99 % | $ 780 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
1.36 B | $ 245.39 | 0.76 % | $ 15 B |  Irlanda |
 |
Zai Lab Limited
ZLAB
|
-151 M | $ 26.56 | -1.12 % | $ 29.1 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-125 M | $ 1.8 | 3.16 % | $ 129 M | USA |
 |
CohBar
CWBR
|
-10.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Zoetis
ZTS
|
2.9 B | $ 82.45 | 0.15 % | $ 36.6 B | USA |
 |
NeuBase Therapeutics
NBSE
|
-5.69 M | - | -1.56 % | $ 12.3 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-8.13 M | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
-25.6 M | $ 0.85 | -5.53 % | $ 17.5 M | USA |
 |
scPharmaceuticals
SCPH
|
-70.5 M | - | - | $ 218 M | USA |
 |
Johnson & Johnson
JNJ
|
24.5 B | $ 281.13 | -0.35 % | $ 677 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-32 M | $ 0.17 | -2.59 % | $ 1.39 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-43 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
-59 M | - | 3.77 % | $ 22.4 M | USA |
 |
Global Blood Therapeutics
GBT
|
-257 M | - | - | $ 4.62 B | USA |
 |
Longeveron
LGVN
|
-18.6 M | $ 2.77 | 37.81 % | $ 48.7 B | USA |
 |
Inozyme Pharma
INZY
|
-91.9 M | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
-24.5 M | - | -23.04 % | $ 26.6 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
55.8 M | $ 94.4 | 1.31 % | $ 4.74 B | USA |
 |
NanoString Technologies
NSTG
|
-129 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
-76.7 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-294 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-59.6 M | - | - | $ 59.7 M | USA |
 |
Sierra Oncology
SRRA
|
-79 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-8.19 M | $ 1.03 | -6.33 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-132 M | $ 4.24 | -3.97 % | $ 346 M | USA |
 |
Nektar Therapeutics
NKTR
|
-209 M | $ 37.82 | -0.01 % | $ 638 M | USA |
 |
Vaccinex
VCNX
|
-16.2 M | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-2.6 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-18.9 M | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
-28.9 M | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-122 M | - | - | $ 69.7 B |  Britain |
 |
Corner Growth Acquisition Corp.
COOL
|
-21.6 K | - | -0.89 % | $ 114 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 7.0 | -8.62 % | $ 471 B | Britain |
 |
Mersana Therapeutics
MRSN
|
-82.3 M | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
7.77 B | $ 54.08 | -3.08 % | $ 3.5 B |  Danmark |
 |
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-15.9 M | - | - | $ 717 K | USA |